secwatch.observer — SEC 8-K summary
======================================

Issuer:     Mirum Pharmaceuticals, Inc. (MIRM)
CIK:        0001759425
Form:       8-K
Filed at:   2024-01-08T23:59:59+00:00
Accession:  0001193125-24-003965
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Mirum announces preliminary 2023 net product sales of $178-180M; LIVMARLI sales up 89% YoY
--------------------------------------------------------------------------------

- Preliminary 2023 total revenue $186-188M; net product sales $178-180M.
- LIVMARLI net product sales $141-143M, ~89% YoY growth.
- Q4 2023 net product sales $69-71M (LIVMARLI $41-43M; CHOLBAM & CHENODAL ~$28M).
- FDA PDUFA for LIVMARLI in PFIC on March 13, 2024; NDA submission for CHENODAL in CTX in H1 2024.
- Appointed Eric Bjerkholt as CFO; company fully financed with strong balance sheet.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1759425/000119312524003965/0001193125-24-003965-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1759425/000119312524003965/d754126d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-003965

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer